Cellular macromolecules in hypoxic tumor microenvironment

Cellular macromolecules in the hypoxic tumor microenvironment refer to the collective biological components, primarily DNA, that serve as the ultimate targets for hypoxia-activated prodrugs (HAPs). In solid tumors, rapid and disorganized growth often outpaces the blood supply, creating regions of chronic or acute hypoxia that are notoriously resistant to conventional radiotherapy and chemotherapy (Brown, 1993, Cancer Research). HAPs are designed as relatively non-toxic molecules that undergo bioreductive activation by intracellular enzymes specifically in these low-oxygen environments, where the absence of oxygen prevents the reversal of the initial reduction step. Once activated, these drugs generate highly reactive species, such as free radicals or alkylating agents, that form covalent adducts with or induce strand breaks in DNA and other vital macromolecules (Hunter et al., 2016, Nature Reviews Cancer). This localized activation turns the tumor's physiological stress into a therapeutic trigger, aiming to selectively kill malignant cells in the most treatment-resistant areas while sparing well-oxygenated healthy tissues. Despite the theoretical elegance of this approach, clinical success has been hampered by the heterogeneity of tumor oxygenation and the challenge of delivering prodrugs into poorly vascularized tumor cores (Wilson & Hay, 2011, Nature Reviews Cancer).

Other names

Hypoxic tumor microenvironment macromoleculesHypoxia-targeted cellular componentsBioreductive drug targets

Hypoxia-activated prodrugs (HAPs) undergo enzymatic reduction by intracellular reductases (such as cytochrome P450 or POR) specifically in low-oxygen environments to generate reactive cytotoxic species. These reactive intermediates then damage cellular macromolecules, primarily by inducing DNA strand breaks or forming DNA alkylation adducts, leading to apoptosis in hypoxic tumor regions (Hunter et al., 2016, Nature Reviews Cancer).